Core Viewpoint - Gene therapy is emerging as a revolutionary treatment method in the biopharmaceutical field, with companies like Hangzhou Jiayin Biotechnology aiming to make it more accessible and affordable for patients [6][10]. Company Overview - Hangzhou Jiayin Biotechnology, established in 2019, focuses on gene therapy and has developed multiple research pipelines in ophthalmology and neurology [6][8]. - The company has successfully advanced three projects to clinical stages within five years, emphasizing innovation as a key driver [11]. Product Development - The company’s gene therapy product EXG102-031 has received FDA approval for clinical trials in the U.S. and is currently in Phase III trials after completing Phase II in China [7][8]. - EXG102-031 targets age-related macular degeneration, offering a single injection solution that can effectively express therapeutic proteins to prevent abnormal blood vessel formation [8]. - Another product, EXG001-307, is aimed at treating spinal muscular atrophy (SMA) and has shown promising results in clinical trials, with all treated patients surviving without respiratory support [9][10]. Innovation and Infrastructure - The company has established a GMP production platform covering over 12,000 square meters, which supports the entire gene therapy production chain and aims to reduce costs through optimized processes [11][12]. - A highly qualified research team, with over 50% holding master's degrees or higher, drives the company’s innovation efforts [12]. Industry Context - The gene therapy market in China is still in its infancy, with few participants, but is expected to grow significantly as companies like Hangzhou Jiayin Biotechnology push forward [11]. - The company believes that private enterprises play a crucial role in technological innovation, particularly in the biopharmaceutical sector, due to their agility and collaborative capabilities [12].
杭州嘉因生物:做出惠及大众的划时代创新药
Mei Ri Shang Bao·2025-09-17 22:23